AddLife: Re-igniting the Life Science compounder - Redeye

Redeye initiates coverage of AddLife, a specialized European serial acquirer operating across Medtech and Labtech. Following three years of disciplined operational deleveraging the balance sheet is fully restored. Backed by resilient, non-cyclical healthcare demand and strong working capital conversion, AddLife is well positioned to step up M&A deployment and resume long-term earnings compounding.

Länk till analysen i sin helhet: https://www.redeye.se/research/1185500/addlife-re-igniting-the-life-science-compounder?utm_source=finwire&utm_medium=RSS